VASH2 and pachyonychia congenita: It is known that EMT can promote gemcitabine resistance and invasion of tumor cells.15 After measuring the IC50 of gemcitabine in BxPC‐3 and PANC‐1 cells (Figure 3), we examined the impact of VASH2 expression on the apoptosis of PC cells after treating VASH2‐overexpressing BxPc‐3 cells and control BxPc‐3 cells with 1.0‐20 μg/mL gemcitabine, and PANC‐1 cells with VASH2 knockdown and control PANC‐1 cells with 10‐60 μg/mL gemcitabine, respectively.